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AbstrAct
Objective evaluate the performance of FraX®, with and 
without bone mineral densitometry (BMD), in predicting the 
occurrence of fragility fractures over 10 years.
Methods Participants aged ≥40 years at baseline, with 
a complete set of data and a minimum of 8.5 years of 
follow-up were identified from three cohorts (n=2626). 
ten-year fracture risk at baseline were estimated with 
FraX® and assessed by comparison with observed 
fractures and receiver operating characteristic analysis.
Results During a mean (SD) follow-up of 9.12 (1.5) years, 
178 participants suffered a major osteoporotic (MOP) fracture 
and 28 sustained a hip fracture. the predictive performance 
of FraX® was superior to that of BMD alone for both MOP 
and hip fractures. the area under the curve (aUc) of FraX® 
without BMD was 0.76 (95% ci 0.72 to 0.79) for MOP 
fractures and 0.78 (95% ci 0.69 to 0.86) for hip fractures. no 
significant improvements were found when BMD was added 
to clinical variables to predict either MOP (0.78, 95% ci 0.74 
to 0.82, p=0.25) or hip fractures (0.79, 95% ci 0.69 to 0.89, 
p=0.72). aUcs for FraX® (with and without BMD) were 
greater for men than for women. FraX®, with and without 
BMD, tended to underestimate the number of MOP fractures 
and to overestimate the number of hip fractures in females. 
in men, the number of observed fractures were within the 
95% ci of the number predicted, both with and without BMD.
Conclusion FraX® without BMD provided good fracture 
prediction. adding BMD to FraX® did not improve the 
performance of the tool in the general population.
InTROduCTIOn
Osteoporotic fractures currently represent an 
enormous social and economic burden world-
wide,1 which will tend to increase persistently 
due to the progressive ageing of the popula-
tion and other societal changes,2 unless effec-
tive preventive measures are taken.
For cost-effectiveness purposes, preventive 
strategies should be based on the absolute 
risk of osteoporotic fractures in the individual 
patient. FRAX®3 4 is the most widely used tool 
to estimate osteoporotic fracture probabili-
ties,5 and it has been incorporated in a large 
number of guidelines for the prevention and 
management of osteoporosis.2 6–9 FRAX® esti-
mates are based on a set of easily assessable 
clinical risk factors, with or without consider-
ation of femoral neck bone mineral density 
(BMD),4 making it a feasible tool, even in 
technically deprived environments.
Given the differences in the incidence of 
major osteoporotic (MOP) fractures between 
countries,10 11 FRAX® should be validated in 
Key messages
What is already know about this subject?
 ► FraX® has been validated and is used in a 
large number of countries to estimate the risk of 
osteoporotic fractures, thus informing individual 
treatment, societal preventive strategies and 
national guidelines to initiate treatment. However, a 
recent systematic literature review identified a large 
number of important limitations and caveats in the 
available studies.
What does this study add?
 ► this study provides a methodologically robust 
piece of evidence supporting the predictive value 
of FraX® (area under the curve: 0.72 to 0.93) in a 
general population setting. it also demonstrates, for 
the first time that, at a global level, the performance 
of this tool is not enhanced by considering bone 
mineral density in addition to immediately available 
clinical risk factors.
How might this impact on clinical practice?
 ► the data presented on this study substantially adds, 
in quantity and quality, to the evidence supporting 
the use of FraX® to estimate the risk of fracture 
and serve as a reference in the decision to treat. 
the data indicates that, overall, estimates based 
solely on the clinical risk factors included in the 
algorythmhave a similar reliability, questionning the 
need for systematic assessment of bone mineral 
density.
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national cohorts to optimise its predictive value in each 
country.4 A recent systematic review12 demonstrated that 
this has not always been done and that most validation 
studies have significant bias, especially recruitment bias 
regarding the target population, and missing data on 
clinical risk factors. Few of these studies worldwide have 
been conducted in the general population.12
The purpose of this study was to evaluate the perfor-
mance of FRAX® in predicting the 10-year probability 
of osteoporotic fractures using data from three prospec-
tive cohorts from the general population. We also investi-
gated the value of adding BMD to the clinical parameters 
of FRAX®.
MeTHOds
For this study, data of three different Portuguese cohorts, 
SAOL, IPR and EPIPorto (from centre, south and north 
of the country, respectively), were combined. Only 
persons aged >40 years and with a complete set of data 
on FRAX® clinical risk factors were included. There were 
no other exclusion criteria.
More details on cohorts and selection of partici-
pants can be found on online supplementary material. 
Online supplementary figure 1 shows the disposition of 
participants during follow-up and numbers used for data 
analysis.
BMd evaluation
Dual energy X-ray absorptiometry (DXA) scans of the 
spine and proximal femur of the non-dominant side were 
performed at the baseline visit of all participants, using 
a Hologic QDR 4500/c bone densitometer in all cases. 
A daily quality exam was performed every day to ensure 
the quality of the exams performed in the bone densi-
tometer (as recommended by the manufacture); a well-
trained technician in every cohort performed the exams. 
Participants without femoral BMD measurement at base-
line were excluded. Hip T scores were used as provided 
by the bone densitometer on the basis of NHANES III 
(Third National Health and Nutrition Examination 
Survey) reference values.13
Fractures
The first new fracture during follow-up and the date on 
which it occurred were self-reported at the follow-up visit 
in all cohorts. In the SAOL cohort, fracture reports were 
confirmed by clinical file review in all but 2 of 52 frac-
tures.
The fracture outcome of interest in this analysis was 
new first hip fracture and fracture of either the hip, wrist, 
shoulder or clinical fracture of the spine (MOP), regard-
less of the degree of trauma, so as to conform to the defi-
nition of hip, and MOP fracture by FRAX®.
FRAX® predictions
The 10-year fracture risk estimates for hip and MOP frac-
tures (with and without adding the variable femoral neck 
BMD) for each individual case were assessed using the 
Portuguese version of the FRAX® tool by an operator 
who was blinded for the fracture outcomes. All variables 
were defined exactly as prescribed by FRAX®.
All three cohort studies had been approved by local 
ethics committees, and informed consent had been 
obtained from all patients. The Research Ethics Board of 
Faculty of Medicine of Coimbra University approved the 
current analysis.
sTATIsTICs
Follow-up time for the fracture analyses was truncated at 
10 years, when applicable, to correspond with the 10-year 
fracture risk estimates from FRAX®. Of participants who 
deceased during follow-up (n=292), fracture data were 
collected from family members and included in the anal-
yses, according to the assumption of the tool.10 Data for 
survival analyses was censored at the date of first fracture, 
date of death or 10 years without fractures or end of 
follow-up before 10 years without fractures (as described 
in Methods, participants from EPIPorto did not complete 
10 years of follow-up).
Descriptive statistics for demographic and baseline 
characteristics are presented as mean (SD) or median 
(IQR) for continuous variables or count (percentage) for 
categorical variables.
Crude comparisons of parameters of participants with 
fractures versus those with no fractures were performed 
with χ2 tests and Mann-Whitney U test.
Cox proportional hazards models were constructed 
for MOP and for hip fracture prediction separately, to 
assess the contributions of the individual FRAX® vari-
ables. Cox proportional hazards takes time into account, 
thus the shorter duration of follow-up in EPIPorto was 
not an issue for those who had a first new fracture during 
this follow-up. Receiver operating characteristic (ROC) 
area under the curve (AUC) analyses were conducted 
to explore the fracture risk stratification using FRAX® 
with and without BMD and the prediction of BMD 
alone (femoral neck T score or minimum value at any 
site). An AUC of 0.50 indicates a result no better than 
chance, an AUC >0.5–0.6 or <0.5–0.4: poor discrimina-
tive value, 0.6–0.8 or 0.2–0.4: moderate discriminative 
value and >0.8 or <0.2: high discriminative value14; only 
AUCs with CI excluding 0.5 are statistically significant. 
Pairwise comparison of AUCs ROC was performed using 
MedCalc (V.14.8.1). Sensitivity analyses were performed 
by excluding data from EPIPorto given their shorter 
follow-up. Kaplan-Meier curves were plotted, showing 
fracture incidence over time by cohort.
We assessed the fit of predicted values of FRAX® by 
comparing the observed proportion of participants 
who sustained a first new fracture with the proportion 
predicted by FRAX®. These analyses were undertaken in 
the entire cohort and then repeated in the cohort divided 
into clinically relevant subgroups for age and gender.
Statistical analyses were performed with SPSS for 
Windows (V.20.0). We applied STROBE (Strengthening 
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the reporting of oservational studies in epidemiology) 
criteria for cohort studies to ensure the quality of 
our study.15 A p value of <0.05 was taken as statistically 
significant.
ResulTs
The study sample with baseline and follow-up observa-
tions consisted of 2626 participants (1943 women (73%) 
and 683 (27%) men). Baseline characteristics are summa-
rised in table 1. The mean (SD) age at baseline was 58.2 
(10.2) years; during follow-up, 292 (11.1%) participants 
had died from different causes. The most prevalent 
among FRAX® clinical risk factors was ‘secondary osteo-
porosis’ (24.3%), and the least prevalent was rheumatoid 
arthritis (4.9%).
During follow-up, with a mean (SD) duration of 9.12 
(1.5) years (minimum and a total 23 949 person/years), 
28 (1.1%) of these participants suffered from an incident 
hip fracture (median FRAX®-estimated risk at baseline 
for hip fracture: without BMD 2.8% (1.4–4.8); with BMD 
6.9% (1.9–11.8)) and 178 (6.8%) had an incident MOP 
(median FRAX®-estimated risk at baseline for MOP: 
without BMD 6.7% (3.9–10); with BMD 8.9% (5.2–14)). 
More details can be found in online supplementary table 
1.
In table 2, we present the ROC AUC for FRAX® esti-
mates, with and without BMD, as well as ROC AUC for 
DXA alone. The performance of FRAX® is superior to 
that for DXA alone, for both MOP and hip fractures, in 
both men and women. Please see also online supplemen-
tary figures 2 and 3.
AUCs based on FRAX® were numerically higher when 
including DXA, compared with not including DXA, with 
the exception of hip fractures in men, but none of these 
differences reached statistical significance. AUCs based 
on FRAX® with DXA were higher to those of DXA alone, 
all differences being statistically significant. ROC analyses 
excluding participants from EPIPorto revealed exactly 
the same AUC values, except for a modest increase for 
hip prediction with BMD (AUC 0.80, 95% CI 0.71 to 
0.89) (data not shown).
As shown in table 3, when BMD was not included 
in the model, all clinical risk factors except BMI and 
rheumatoid arthritis were independent predictors of 
new MOP fractures. Regarding new hip fractures, the 
model without BMD retains age and glucocorticoids as 
Table 1 Baseline characteristics of participants and baseline FRAX® risk estimates
All Men Women
N, n (%) 2626 683 (27) 1943 (73.0)
Age, mean (SD) 58.2 (10.2) 60.3 (11.4) 57.7 (9.9)
  40–59, n (%) 1495 (56.9) 352 (51.5) 1143 (58.8)
  60–74, n (%) 950 (36.2) 260 (38.1) 690 (35.5)
  ≥75, n (%) 181 (6.9) 71 (10.4) 110 (5.7)
BMI, mean (SD) 27.3 (4.5) 75.5 (11.9) 66.4 (11.6)
Previous fracture, n (%) 512 (19.5) 153 (22.4) 359 (18.5)
Parent hip fractures, n (%) 213 (8.1) 50 (7.3) 163 (8.4)
Current smoking, n (%) 612 (23.3) 344 (50.4) 268 (13.8)
Oral glucocorticoids, n (%) 182 (6.9) 38 (5.6) 144 (7.4)
Rheumatoid arthritis, n (%) 128 (4.9) 18 (2.6) 110 (5.7)
Secondary osteoporosis, n (%) 639 (24.3) 46 (6.7) 593 (30.5)
Alcohol three or more units day, n (%) 529 (20.1) 287 (42) 242 (12.5)
Femoral neck T score, mean (SD)* −1.54 (1.31) −1.35 (1.40) −1.58 (1.30)
  ≥ −1, n (%) 595 (31.4) 138 (37.7) 457 (29.9)
  −2.5<T<−1, n (%) 867 (45.7) 152 (41.5) 715 (46.7)
  ≤−2.5, n (%) 435 (22.9) 76 (20.8) 359 (23.4)
Median 10 year probability, median (IQR)
  MOP fracture without BMD 2.9 (1.7–5.8) 1.6 (1.6–4.4) 3.0 (1.7–6.2)
  MOP fracture with BMD 3.4 (1.8–6.9) 3.1 (1.7–6) 3.5 (1.9–7)
  Hip fracture without BMD 0.5 (0.2–1.6) 0.5 (0.2–1.6) 0.5 (0.2–1.6)
  Hip fracture with BMD 0.7 (0.2–2.5) 0.95 (0.28–2.93) 0.6 (0.2–2.3)
There were no missing data for any of the clinical risk factors considered by FRAX®.
*Femoral Neck BMD was available for 1897 participants.
BMD, bone mineral density; BMI, body mass index; MOP, major osteoporotic.
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significant predictors associated with a history of parent 
hip fractures.
When BMD was included in the model (table 4), age, 
glucocorticoids, parent hip fractures, previous osteopo-
rotic fracture, current smoking, secondary osteoporosis 
and femoral neck BMD were all independent predictors 
of MOP fractures in our sample. In the model with BMD, 
parental hip fractures showed the largest predicted risk 
for MOP fracture (HR 3.69, 95% CI 2.51 to 5.43) and 
BMD showed the smallest (HR 0.72, 95% CI 0.62 to 0.83).
The only independent predictors of hip fractures were 
age, BMI and femoral neck BMD. Gender, alcohol usage, 
secondary osteoporosis and rheumatoid arthritis were 
not independently associated with either MOP or hip 
fractures.
Table 5 shows the calibration of each calculator by 
comparing the number of observed first new fractures 
and the at baseline estimated risk by FRAX® (95% CI). 
FRAX® with and without BMD underestimated incident 
MOP and overestimated hip fractures in women. In men, 
the observed rates of first new fractures were within the 
95% CI of baseline FRAX® predicted rates.
Regarding age and considering both genders together, 
the observed number of hip fractures was within the 
95% CI of prediction in all ages groups, with the excep-
tion of underestimation of the FRAX® with BMD 
Table 2 ROC area under the curve (AUC) analyses for hip and major osteoporotic fractures
Hip fractures Major osteoporotic fractures
AUC 95% CI p Value AUC 95% CI p Value
Women
  BMD femoral neck alone 0.68 0.66 to 0.71 <0.009 0.66 0.63 to 0.68 <0.001
  FRAX® without BMD 0.72† ns 0.69 to 0.74 <0.001 0.75†*** 0.73 to 0.77 <0.001
  FRAX® with BMD 0.75†‡** ns 0.62 to 0.87 <0.001 0.76†‡*** ns 0.74 to 0.78 <0.001
Men
  BMD femoral neck alone 0.82 0.78 to 0.86 <0.004 0.80 0.76 to 0.84 <0.001
  FRAX® without BMD 0.93†*** 0.89 to 0.95 <0.001 0.81† ns 0.76 to 0.85 <0.001
  FRAX® with BMD 0.90†‡***ns 0.86 to 0.93 <0.001 0.85†‡* ns 0.81 to 0.88 <0.001
Both
  BMD femoral neck alone 0.72 0.61 to 0.83 <0.001 0.69 0.64 to 0.73 <0.001
  FRAX® without BMD 0.78 0.69 to 0.86 <0.001 0.76†*** 0.72 to 0.79 <0.001




†p Value versus same site/gender BMD alone.
‡p Value versus same site/gender FRAX® without BMD.
BMD, bone mineral density; ns, non-significant; ROC, receiver operating characteristic.
Table 3 HRs for fracture based on individual FRAX® variables excluding BMD. All variables are defined as prescribed by 
FRAX®
Hip fractures Major osteoporotic fractures
HR 95% CI p Value HR 95% CI p Value
Sex (men vs women) 0.80 0.31 to 2.08 0.642 1.64 1.05 to 2.55 0.030
Age (years) 1.13 1.08 to 1.18 <0.001 1.04 1.02 to 1.06 <0.001
BMI (kg/m2) 1.05 0.97 to 1.14 0.204 0.98 0.94 to 1.01 0.206
Previous fracture(yes/no) 1.44 0.62 to 3.33 0.393 2.75 2.02 to 3.75 <0.001
Parent hip fractures (yes/no) 3.29 1.31 to 8.19 0.011 3.51 2.48 to 4.98 <0.001
Current smoking (yes/no) 0.95 0.29 to 3.12 0.931 1.32 0.87 to 2.01 0.196
Glucocorticoids (yes/no) 3.33 1.23 to 9.06 0.018 2.99 1.95 to 4.59 <0.001
Rheumatoid arthritis (yes/no) 1.44 0.38 to 5.48 0.594 1.67 0.98 to 2.84 0.058
Secondary osteoporosis (yes/no) 1.34 0.56 to 3.22 0.514 1.61 1.17 to 2.23 0.004
Alcohol three or more units day (yes/no) 0.82 0.27 to 2.48 0.722 1.52 1.04 to 2.21 <0.030
BMD, bone mineral density; BMI, body mass index.
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estimate for the group aged <60 years. For MOP frac-
tures, the baseline FRAX® estimate also underestimated 
the risk for those under the age of 75 years. The agree-
ment between predicted and observed rats above this age 
was better, although the number of observed new first 
fractures was small.
Kaplan-Meier survival models showed that a similar 
number of new first fractures occurs every year in all three 
cohorts (data not shown). Based on this observation, we 
estimated that 12 MOP fractures would have occurred 
in the 2.5 missing years of follow-up in EPIPorto, which 
are unaccounted for. The impact of this difference of 
follow-up was evaluated through sensitivity analysis, as 
described above.
dIsCussIOn
In this study in a cohort of general population, we used 
several approaches to compare the predictive perfor-
mance of baseline FRAX® estimates with and without 
Table 4 HRs for fracture based on individual FRAX® variables including femoral neck BMD
Hip fractures Major osteoporotic fractures
HR 95% CI p Value HR 95% CI p Value
Sex (men vs women) 0.58 0.21 to 1.59 0.287 1.32 0.80 to 2.20 0.276
Age (years) 1.12 1.07 to 1.18 <0.001 1.03 1.01 to 1.05 0.006
BMI (kg/m2) 1.14 1.04 to 1.25 0.007 1.01 0.97 to 1.05 0.598
Previous fracture(yes/no) 1.23 0.48 to 3.11 0.669 2.47 1.72 to 3.55 <0.001
Parent hip fractures (yes/no) 1.44 0.42 to 4.95 0.560 3.69 2.51 to 5.43 <0.001
Current smoking (yes/no) 2.45 0.69 to 8.68 0.165 1.72 1.05 to 2.81 0.031
Glucocorticoids (yes/no) 2.62 0.92 to 7.49 0.072 2.80 1.78 to 4.41 <0.001
Rheumatoid arthritis (yes/no) 1.68 0.42 to 6.69 0.461 1.36 0.74 to 2.48 0.318
Secondary osteoporosis (yes/no) 1.22 0.48 to 3.09 0.673 1.43 1.00 to 2.05 0.049
Alcohol three or more units day (yes/no) 1.14 0.32 to 4.11 0.842 1.30 0.78 to 2.17 0.323
Femoral neck T score 0.60 0.41 to 0.87 0.007 0.72 0.62 to 0.83 <0.001
BMD, bone mineral density; BMI, body mass index.
Table 5 FRAX®-estimated and observed number of first new fractures during follow-up
FRAX® without BMD (n=2626) FRAX® with BMD (n=1986)
Observed Estimated (95% CI) Observed Estimated (95% CI)
Women
  MOP 145 97.5 (78.6 to 116.3) 116 91.3 (73.1 to 109.4)
  Hip 20 30.9 (20.1 to 41.8) 17 35.8 (24.2 to 44.4)
Men
  MOP 33 24.9 (15.3 to 34.6) 23 18.9 (10.6 to 27.2)
  Hip 8 9.9 (3.82 to 16.1) 7 10.3 (4.1 to 16.5)
Women and Men
  MOP 178 122.4 (101.3 to 143.6) 139 116.2 (95.7 to 136.7)
  Hip 28 40.9 (28.4 to 53.3) 24 48.7 (35.2 to 62.2)
  Age <60 years
  MOP 69 34.7 (23.3 to 46.1) 52 36.8 (25.1 to 48.5)
  Hip 1 5.5 (0.9 to 10.1) 1 12.4 (5.5 to 19.2)
  Age 60–75 years
  MOP 97 67 (51.5 to 82.5) 77 60.4 (45.9 to 75)
  Hip 21 24.1 (14.6 to 33.7) 18 26.3 (16.5 to 36.1)
  Age >75 years
  MOP 12 21 (12.7 to 29.3) 10 13.7 (7.08 to 20.3)
  Hip 6 11.4 (5.06 to 17.8) 5 7.8 (2.6 to 13)
BMD, bone mineral density; MOP, major osteoporotic.
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BMD with observed first new fractures during follow-up. 
FRAX® is designed to predict the risk of fracture and 
does not distinguish the risk of multiple fractures in one 
individual. That is why our data were censored at the first 
fracture.
AUC ROC values of baseline FRAX® estimates ranged 
from 0.78 to 0.79 for hip fracture and from 0.76 to 0.78 
for MOP fracture, indicating moderate discriminative 
ability of FRAX®, with and without BMD, for predicting 
both hip and MOP fractures in both genders. The AUC 
ROC values for BMD alone were 0.72 for hip fractures 
and 0.69 for MOP fracture. FRAX® estimates with and 
without BMD have a better performance than has BMD 
alone. No significant differences were found between the 
predictive performance of FRAX® estimates with and 
without BMD.
The prediction of first new hip fractures was more reli-
able than that of MOP fractures, which is in agreement 
with previous studies.16–22 The performance of the tool 
was higher in males than in females, for both groups of 
fractures.18 23
AUC ROC values found in our study are generally 
higher than those found in a recent meta-analysis.12 
This may be related to the higher quality of methods 
used in our study and the full respect for the conditions 
of FRAX® applicability predicted in its development 
process4 10; in contrast with most previous studies, we 
included participants from the general population and 
considered all clinical risk factors included in FRAX® 
using the exact definitions provided by the tool; we only 
included cases with a complete set of clinical data, and 
we accounted for participants who died during follow-up. 
Our only limitation in this respect was the shorter dura-
tion of follow-up in one of the cohorts. The prevalence 
of clinical risk factors was similar to other studies, with 
exception of secondary osteoporosis and consumption of 
alcohol and tobacco that were higher in our study, which 
may be related to the systematic questioning about these 
risk factors. We also found that the individual risk factors 
used by FRAX® had significant independent contribu-
tions to fracture prediction. Age and glucocorticoid use 
were strongly associated with new first MOP and hip frac-
ture risk in both models (with and without BMD).
FRAX®, with and without BMD, underestimated inci-
dent MOP and overestimated hip fractures in women, 
while in men the observed number of both types of 
fractures was within the 95% CI of the prediction, both 
with and without BMD. These results are similar with 
those found in other studies16 20 21 24 25 and a systematic 
review.26 We hypothesise that the discrepancies between 
the observed and predicted rates of fractures in females 
may be related to the fact that for the construction of 
Portuguese FRAX® algorithm, we have only used actual 
national epidemiological data for hip fractures, the rate 
for the MOP fractures being estimated using Swedish 
age specific ratios.27 When considering age, the number 
of observed first new MOP fractures was higher than 
estimated until the age of 75 years. There was good agree-
ment regarding hip fractures in all age groups.
Overall, our results show that the FRAX® algorithm 
with clinical risk factors has a better performance at 
predicting the rate of first new fractures than BMD alone. 
This is in agreement with previous studies.3 18 They also 
demonstrate that adding BMD to the clinical risk factors 
brings no improvement to FRAX® prediction, in terms of 
AUC ROC or rates of observed versus predicted fractures. 
This is the case in both men and women, MOP and hip 
fractures. The impact of DXA on FRAX® performance 
has, to the best of our knowledge, not been investigated 
before. Our observations question the cost-effectiveness 
of DXA measurements for the purpose of predicting frac-
tures in the general population.
Some limitations of this study need to be acknowledged. 
Our dropout rate was 25.2%, which is considerable, 
although similar to that reported in other prospective 
cohort studies of FRAX®.28–30 Patients lost to follow-up 
did not differ significantly for those included in the anal-
yses in terms of clinical risk factors included in FRAX® 
(data not shown). Fracture events were self-reported and 
only confirmed in the SAOL cohort by clinical file review. 
During follow-up, 7.6% of participants used antiosteo-
porotic agents at some time, which reflects the low rate 
of treatment of osteoporosis in the general Portuguese 
population.31 Such treatment may have prevented some 
fractures, potentially contributing to the overestimation 
of the fracture risk, even though recent studies have 
been unable to show this effect in open population-based 
studies.32 33 We investigated the performance of FRAX® 
Portugal,we are unable to comment on the calibration 
or discrimination of other country-specific FRAX® tools. 
Follow-up in the EPIPorto cohort was shorter than the 
10-year timeline of FRAX®. This did not have a relevant 
impact regarding the ROC analyses but may have artifi-
cially reduced, although slightly, the underestimation of 
the actual number of fractures by FRAX®.
Our study has several strengths: it is a multicentre 
cohort of participants recruited from the general popula-
tion, the average duration of follow-up was 8.7 years, the 
clinical risk factors included in FRAX® were collected 
in all participants and we also considered death hazard. 
These qualities support the validity of the results in the 
population expected to receive the test in daily practice.
The FRAX® tool has been incorporated in the clinical 
guidelines for osteoporosis of several countries.34 The 
data presented in this paper have already influenced the 
recent Portuguese recommendations35; both the require-
ment of DEXA (Dual-energy X-ray absorptiometry) and 
the initiation of treatment are based on estimates of the 
actual risk of fracture by FRAX®, with or without BMD 
T scores
COnClusIOn
A moderate performance of FRAX® was found in both 
men and women, with higher AUCs ROC than those 
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reported in the derivation and validation cohorts studied 
by the WHO Collaborating Centre3 and considered in a 
recent meta-analyses.12 The performance was better for 
hip than for MOP fractures, in males than in females, 
and in participants over the age of 75 years. Adding BMD 
to the model did not improve FRAX® performance.
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